Fortress Biotech Pref Preferred Stock Current Ratio
| FBIOP Preferred Stock | USD 5.91 0.71 13.65% |
Fortress Biotech Pref fundamentals help investors to digest information that contributes to Fortress Biotech's financial success or failures. It also enables traders to predict the movement of Fortress Preferred Stock. The fundamental analysis module provides a way to measure Fortress Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Fortress Biotech preferred stock.
Fortress |
Fortress Biotech Pref Company Current Ratio Analysis
Fortress Biotech's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Fortress Biotech Current Ratio | 2.85 X |
Most of Fortress Biotech's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fortress Biotech Pref is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, Fortress Biotech Pref has a Current Ratio of 2.85 times. This is 2.06% lower than that of the Biotechnology sector and 59.29% lower than that of the Health Care industry. The current ratio for all United States preferred stocks is 31.94% lower than that of the firm.
Fortress Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fortress Biotech's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the preferred stocks which would be a good addition to a portfolio. Peer analysis of Fortress Biotech could also be used in its relative valuation, which is a method of valuing Fortress Biotech by comparing valuation metrics of similar companies.Fortress Biotech is currently under evaluation in current ratio category among its peers.
Fortress Fundamentals
| Return On Equity | -1.43 | ||||
| Return On Asset | -0.35 | ||||
| Profit Margin | (1.17) % | ||||
| Operating Margin | (2.63) % | ||||
| Current Valuation | 2.58 B | ||||
| Shares Outstanding | 56.68 M | ||||
| Shares Owned By Institutions | 1.80 % | ||||
| Number Of Shares Shorted | 245 | ||||
| Price To Sales | 1.36 X | ||||
| Revenue | 68.79 M | ||||
| Gross Profit | (85.66 M) | ||||
| EBITDA | (46.05 M) | ||||
| Net Income | (164.83 M) | ||||
| Cash And Equivalents | 248.77 M | ||||
| Cash Per Share | 2.31 X | ||||
| Total Debt | 46.56 M | ||||
| Debt To Equity | 0.81 % | ||||
| Current Ratio | 2.85 X | ||||
| Book Value Per Share | 0.57 X | ||||
| Cash Flow From Operations | (116.54 M) | ||||
| Short Ratio | 0.02 X | ||||
| Earnings Per Share | (0.86) X | ||||
| Number Of Employees | 173 | ||||
| Beta | 1.9 | ||||
| Market Capitalization | 107.79 M | ||||
| Total Asset | 396.5 M | ||||
| Z Score | 1.2 | ||||
| Annual Yield | 0.12 % | ||||
| Net Asset | 396.5 M |
About Fortress Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fortress Biotech Pref's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fortress Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fortress Biotech Pref based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Fortress Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Fortress Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fortress Biotech will appreciate offsetting losses from the drop in the long position's value.Moving against Fortress Preferred Stock
| 0.52 | GRCE | Grace Therapeutics, Symbol Change | PairCorr |
| 0.37 | EVFM | Evofem Biosciences | PairCorr |
| 0.32 | EPRX | Eupraxia Pharmaceuticals | PairCorr |
| 0.32 | GMNI | Gemini Group Global | PairCorr |
The ability to find closely correlated positions to Fortress Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Fortress Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Fortress Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Fortress Biotech Pref to buy it.
The correlation of Fortress Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Fortress Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Fortress Biotech Pref moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Fortress Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Fortress Preferred Stock Analysis
When running Fortress Biotech's price analysis, check to measure Fortress Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fortress Biotech is operating at the current time. Most of Fortress Biotech's value examination focuses on studying past and present price action to predict the probability of Fortress Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fortress Biotech's price. Additionally, you may evaluate how the addition of Fortress Biotech to your portfolios can decrease your overall portfolio volatility.